UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (date of earliest event reported): November
18, 2015
BioTime,
Inc.
(Exact name of registrant as specified in its charter)
California
|
1-12830
|
94-3127919
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
1301
Harbor Bay Parkway
Alameda,
California 94502
(Address
of principal executive offices)
(510)
521-3390
(Registrant's
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Forward-Looking Statements
Any statements that are not historical fact (including, but not
limited to statements that contain words such as “may,” “will,”
“believes,” “plans,” “intends,” “anticipates,” “expects,” “estimates,”
should also be considered to be forward-looking statements. Additional
factors that could cause actual results to differ materially from the
results anticipated in these forward-looking statements are contained in
BioTime’s periodic reports filed with the SEC under the heading “Risk
Factors” and other filings that BioTime may make with the Securities and
Exchange Commission. Undue reliance should not be placed on these
forward-looking statements which speak only as of the date they are
made, and the facts and assumptions underlying these statements may
change. Except as required by law, BioTime disclaims any intent or
obligation to update these forward-looking statements.
This Report and any accompanying exhibits shall be deemed “furnished”
and not “filed” under the Securities Exchange Act of 1934, as amended.
Section 7 - Regulation FD
Item 7.01 - Regulation FD Disclosure
On November 18, 2015, BioTime, Inc. issued the press release furnished
as Exhibit 99.1, which is incorporated by reference.
Section 9 - Financial Statements and Exhibits
Item 9.01 - Financial Statements and Exhibits.
Exhibit Number
|
Description
|
99.1
|
Press release dated November 18, 2015
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
BIOTIME, INC.
|
|
|
|
|
|
|
|
|
|
|
Date:
|
November
18, 2015
|
By:
|
/s/ Michael D. West
|
|
|
|
|
Chief Executive Officer
|
Exhibit Number
|
Description
|
99.1
|
Press release dated November 18, 2015
|
2
Exhibit 99.1
BioTime,
Inc. Announces the Appointment of Life Sciences Industry Veteran Russell
Skibsted as Chief Financial Officer
ALAMEDA, Calif.--(BUSINESS WIRE)--November 18, 2015--BioTime, Inc. (NYSE
MKT and TASE: BTX), a clinical-stage regenerative medicine company with
a focus on pluripotent stem cell technology, today announced that the
Company’s Board of Directors has appointed Russell Skibsted to the
position of Chief Financial Officer, succeeding Robert Peabody.
Mr. Russell Skibsted brings over 25 years of financial management and
life sciences business experience to BioTime. He has served as CFO for
both public and private life sciences companies. Immediately prior to
joining the BioTime team, Russell was CFO at Proove Biosciences, a
commercial-stage diagnostics and personalized medicine company.
Previously he was Senior Vice President, CFO, and Secretary of Aeolus
Pharmaceuticals, a biotechnology company that received over $150M in
government funding in the biodefense and oncology sectors. Mr. Skibsted
also served as SVP and Chief Business Officer of Spectrum
Pharmaceuticals, a commercial-stage pharmaceutical company, and as CFO
of Hana Biosciences. During his tenure at these companies, Mr. Skibsted
successfully raised several investment rounds, including both public and
private offerings as well as corporate partnerships, while raising the
profile of these companies and developing strong relationships with
institutional investors and analysts. Earlier in his career, Mr.
Skibsted was Partner and CFO at Asset Management Company, one of the
oldest and most respected venture capital firms in Silicon Valley. Mr.
Skibsted holds an MBA from the Stanford Graduate School of Business, and
a BA from Claremont McKenna College.
“The addition of Russell to our team is consistent with our commitment
to evolve the management of BioTime as we prepare for later stage
clinical trials and future commercial operations,” commented Adi
Mohanty, BioTime’s co-CEO. “I’m confident that Russell’s proven
leadership and experience in a wide range of public and private life
sciences companies will strengthen our team and help us to create more
value for our shareholders.”
“I am excited to join BioTime,” said Skibsted. “BioTime is clearly a
leader in regenerative medicine with a strong foundation in science and
intellectual property. As the company progresses its therapies for
patients with chronic and degenerative diseases, I look forward to
helping BioTime to maintain a strong financial position so that we are
ready for the next phase of growth and development.”
Robert W. Peabody has served as BioTime’s CFO since he joined the
company in 2007. Working with co-CEO Dr. Michael West, he has helped
BioTime to acquire and develop leading regenerative medicine assets,
including both products under development and a large patent estate,
thereby successfully repositioning the company to have multiple
clinical-stage programs and leadership of the pluripotent stem cell
field. Mr. Peabody has been instrumental in the development of several
early stage companies, having been a co-founder of both Geron and Ocata
Therapeutics, and having helped to create Asterias Therapeutics. He is
joining LifeMap Solutions to apply his early stage expertise in
assisting the company on its business strategy, vision, and equity
capital raising, among other activities. Mr. Peabody stated that, “I
want to welcome Russell to the team, and say that in an effort to
accelerate the overall BioTime growth strategy, I will be available for
consultation to ensure continuity and a smooth transition.”
About BioTime
BioTime, Inc., a pioneer in regenerative medicine, is a clinical-stage
biotechnology company. BioTime and its subsidiaries are leveraging their
industry-leading experience in pluripotent stem cell technology and a
broad intellectual property portfolio to facilitate the development and
use of cell-based therapies and gene marker-based molecular diagnostics
for major diseases and degenerative conditions for which there presently
are no cures. The lead clinical programs of BioTime and its subsidiaries
include OpRegen®, currently in a Phase I/IIa
trial for the treatment of the dry form of age-related macular
degeneration; AST-OPC1, currently in a Phase I/IIa trial for spinal cord
injuries; Renevia™, currently in a pivotal trial in Europe as an
injectable matrix for the engraftment of transplanted cells to treat
HIV-related lipoatrophy; and cancer diagnostics, nearing the completion
of initial clinical studies for the detection of lung, bladder, and
breast cancers. AST-VAC2, a cancer vaccine, is in the pre-clinical trial
stage.
BioTime’s subsidiaries include the publicly traded Asterias
Biotherapeutics, Inc. (NYSE MKT: AST), developing pluripotent stem
cell-based therapies in neurology and oncology, including AST-OPC1 and
AST-VAC2; Cell Cure Neurosciences Ltd., developing stem cell-based
therapies for retinal and neurological disorders, including OpRegen®;
OncoCyte Corporation, developing cancer diagnostics; LifeMap Sciences,
Inc., developing and marketing an integrated online database resource
for biomedical and stem cell research; LifeMap Solutions, Inc., a
subsidiary of LifeMap Sciences, developing mobile health (mHealth)
products; ES Cell International Pte Ltd, which has developed
cGMP-compliant human embryonic stem cell lines being marketed; OrthoCyte
Corporation, developing therapies to treat orthopedic disorders,
diseases, and injuries; and ReCyte Therapeutics, Inc., developing
therapies to treat a variety of cardiovascular and related ischemic
disorders.
BioTime common stock is traded on the NYSE MKT and TASE under the symbol
BTX. For more information, please visit www.biotimeinc.com or
connect with the company on Twitter, LinkedIn, Facebook, YouTube,
and Google+.
FORWARD-LOOKING STATEMENTS
Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for BioTime and its subsidiaries, along with
other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including, but
not limited to statements that contain words such as “will,” “believes,”
“plans,” “anticipates,” “expects,” “estimates”) should also be
considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, and maintenance of
intellectual property rights. Actual results may differ materially from
the results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that affect the
business of BioTime and its subsidiaries, particularly those mentioned
in the cautionary statements found in BioTime’s Securities and Exchange
Commission filings. BioTime disclaims any intent or obligation to update
these forward-looking statements.
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://news.biotimeinc.com.
CONTACT:
BioTime, Inc.
Dan L. Lawrence, 510-775-0510
dlawrence@biotimeinc.com
or
EVC
Group, Inc.
Michael Polyviou, 646-445-4800
mpolyviou@evcgroup.com
or
Media
Contact:
Gotham Communications, LLC
Bill Douglass, 646-504-0890
bill@gothamcomm.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Apr 2024 to May 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From May 2023 to May 2024